BioAlliance Pharma extends Loramyc licence to China

Published: 24-Jun-2008
Regulatory

French speciality pharmaceutical company BioAlliance Pharma, which focuses on the treatment of opportunistic infections in cancer and HIV, has entered into an exclusive licensing agreement under which NovaMed Pharmaceuticals will receive commercialisation rights in China for Loramyc.


French speciality pharmaceutical company BioAlliance Pharma, which focuses on the treatment of opportunistic infections in cancer and HIV, has entered into an exclusive licensing agreement under which NovaMed Pharmaceuticals will receive commercialisation rights in China for Loramyc.

Loramyc (miconazole Lauriad), BioAlliance Pharma's innovative, muco-adhesive antifungal therapy, is already approved in Europe and completed a Phase III clinical trial in the US in immunocompromised patients.

NovaMed is a new pharmaceutical entity in China, founded in 2005, that acts as a middleman for companies with drugs they would like to sell or test in China acting through the Chinese regulatory process to commercialisation. The company organises manufacture, distribution and sales of pharmaceutical products.

BioAlliance's partnership with NovaMed could potentially generate US$4.5m (Euro 2.9m) through a combination of licensing cash on signing and milestones. Royalty commensurate with the product stage will also be received. NovaMed plans to register the product in China and launch Loramyc immediately after gaining marketing approval from the Chinese authority.

"Novamed has rapidly built critical mass in the Chinese oncology market and today enjoys partnering agreements with Baxter, Pfizer and Sanofi-Aventis," said Dominique Costantini, BioAlliance Pharma president and ceo.

"Loramyc is a good fit product-wise and it will strengthen NovaMed's position in the supportive care segment of the fast growing oncology segment in China," added Hao Zhou, vp business development at NovaMed Pharmaceuticals. "NovaMed will continue to seek other partnering opportunities with BioAlliance in the oncology area going forward."

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now